Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
30 participants
INTERVENTIONAL
2008-03-31
2011-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
III
Placebo
Spironolactone
25 mg po qd 25 mg po bid
Experimental
Drug intervention
Spironolactone
25 mg po qd 25 mg po bid
Placebo
Spironolactone 25 mg po qd
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Spironolactone
25 mg po qd 25 mg po bid
Placebo
Spironolactone 25 mg po qd
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Paroxysmal AF.
Exclusion Criteria
2. Creatinine \> 2 mg/dl;
3. Serum potassium \>= 5 mM;
4. Serum sodium \<=130 mM;
5. Uric acid \> 10 mg/dl。
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Taichung Veterans General Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Taichung Veterans General Hospital
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Tsu-Juey Wu, M.D.
Role: PRINCIPAL_INVESTIGATOR
TCVGH
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Taichung General Hospital
Taichung, , Taiwan
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Tsu-Juey Wu, M.D.
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
C07061
Identifier Type: -
Identifier Source: org_study_id